← All organizations
Highest phase reached
Phase 2
First clinical trial
Sep 1, 2008Last known activity
Jul 27, 2021
Timeline
2000s
- Jun 1, 2000
US Biotest— Founded
Drugs by trial phase (7 distinct, 18 trials)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Carcinoma
- Carcinoma in Situ
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Cervical Intraepithelial Neoplasia
- Congenital Abnormalities
- Diabetic Foot
- Foot Ulcer
- Genital Neoplasms, Male
- HIV Infections
- Keratosis
- Keratosis, Actinic
- Kidney Neoplasms
- Lung Neoplasms
- Lymphopenia
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Second Primary
- Neutropenia
- Ovarian Neoplasms
- Preleukemia
- Prostatic Neoplasms
- Psoriasis
- Skin Neoplasms
- Small Cell Lung Carcinoma
- Syndrome
- Thrombocytopenia
- Ulcer
- Urinary Bladder Neoplasms
- Urogenital Neoplasms
- Urologic Neoplasms
Recent trials (27)
- NCT03756311CollaboratorN/A—
- NCT04060628CollaboratorN/A—
- NCT04778059Lead sponsorPhase 2Jul 27, 2021
- NCT04314895Study directorPhase 2May 31, 2020
- NCT04314895CollaboratorPhase 2May 31, 2020
- NCT04260360Study directorPhase 1Apr 30, 2020
- NCT04260360CollaboratorPhase 1Apr 30, 2020
- NCT04221828Study directorPhase 2Mar 31, 2020
- NCT04221828CollaboratorPhase 2Mar 31, 2020
- NCT03636256CollaboratorPhase 1/Phase 2Nov 30, 2018
- NCT03615196Lead sponsorPhase 1Jul 25, 2018
- NCT03143491CollaboratorPhase 2Oct 1, 2017
- NCT03101358Study directorPhase 2Jun 1, 2017
- NCT03101358CollaboratorPhase 2Jun 1, 2017
- NCT03083470CollaboratorPhase 2May 18, 2017
Details
- Founded
- San Luis Obispo, CA, US Jun 1, 2000
- Last known activity
- Jul 27, 2021